Aclaris Therapeutics (ACRS) Accounts Payables (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Accounts Payables of $14.7 million for Q1 2026, up 131.84% year-over-year from $6.4 million in Q1 2025, and up 11.95% quarter-over-quarter from $13.2 million in Q4 2025.
Aclaris Therapeutics (ACRS) Accounts Payables (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Accounts Payables history runs 13 years deep, the most recent figure standing at $14.7 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 131.84% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 131.84% YoY), while the FY2025 annual figure was $13.2 million, up 180.55% from the prior year.
- Accounts Payables for Q1 2026 stood at $14.7 million, up from $13.2 million in the prior quarter.
- The five-year high for Accounts Payables was $14.7 million in Q1 2026, with the low at $4.7 million in Q4 2024.
- The 5-year median for Accounts Payables is $8.8 million (2025), against an average of $9.0 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 47.17% in 2024, then jumped 180.55% in 2025.
- Aclaris Therapeutics' Accounts Payables stood at $10.4 million in 2022, then dropped by 14.23% to $8.9 million in 2023, then slumped by 47.17% to $4.7 million in 2024, then surged by 180.55% to $13.2 million in 2025, then climbed by 11.95% to $14.7 million in 2026.
- Business Quant data shows ACRS's Accounts Payables at $14.7 million in Q1 2026, $13.2 million in Q4 2025, and $9.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 15.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.52 Mn |
| Mar 31, 2026 | 14.73 Mn |
| Dec 31, 2025 | 13.16 Mn |
| Sep 30, 2025 | 9.19 Mn |
| Jun 30, 2025 | 8.80 Mn |
| Mar 31, 2025 | 6.35 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 7.66 Mn |
| Jun 30, 2024 | 7.27 Mn |
| Mar 31, 2024 | 10.81 Mn |
| Dec 31, 2023 | 8.88 Mn |
| Sep 30, 2023 | 9.65 Mn |
| Jun 30, 2023 | 11.43 Mn |
| Mar 31, 2023 | 8.19 Mn |
| Dec 31, 2022 | 10.35 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Jun 30, 2022 | 5.70 Mn |
| Mar 31, 2022 | 8.12 Mn |
| Dec 31, 2021 | 9.99 Mn |
| Sep 30, 2021 | 7.56 Mn |